690afec4-figure-01 (Levetiracetam Oral Solution 1)
Chemical structure of levetiracetam, showing the molecular arrangement of its atoms and bonds.*
Levetiracetam Solution
Product Images NDC 65162-685
8 FDA label images from Amneal Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 65162-685). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
690afec4-figure-02 (Levetiracetam Oral Solution 2)
A bar chart displaying the percentage of patients on the vertical axis. The chart compares three groups: Placebo (N=95) at 7.4%, Levetiracetam 1000 mg/day (N=97) at 37.1%, and Levetiracetam 3000 mg/day (N=101) at 39.6%. Both Levetiracetam groups show significantly higher percentages than Placebo.*
690afec4-figure-03 (Levetiracetam Oral Solution 3)
A bar chart displaying the percentage of patients for three groups: Placebo (6.3%, N=111), Levetiracetam 1000 mg/day (20.8%, N=106), and Levetiracetam 2000 mg/day (35.2%, N=105). The y-axis represents the percentage of patients from 0% to 45%.*
690afec4-figure-04 (Levetiracetam Oral Solution 4)
A bar chart comparing the percentage of patients between two groups: Placebo (N=104) with 14.4% and Levetiracetam 3000 mg/day (N=180) with 39.4%. The y-axis represents the percentage of patients from 0% to 45%, and the x-axis specifies the treatment groups and sample sizes.*
690afec4-figure-05 (Levetiracetam Oral Solution 5)
A bar chart comparing the percentage of patients in two groups: Placebo (N=97) and Levetiracetam (N=101). The y-axis represents the percentage of patients, with the Placebo group showing 19.6% and the Levetiracetam group 44.6%. The chart highlights a notable difference between the two groups.*
Figure 5 (Levetiracetam Oral Solution 6)
A bar chart comparing the percentage of patients between two groups: Placebo (N=51) at 19.6% and Levetiracetam (N=58) at 43.1%. The y-axis represents the percentage of patients, ranging from 0% to 45%. A symbol (*) appears above the Levetiracetam bar.*
690afec4-figure-07 (Levetiracetam Oral Solution 7)
Bar chart comparing the percentage of patients in placebo (45.2%) versus levetiracetam (72.2%) groups. The vertical axis represents percentage of patients from 0% to 100%, with sample sizes noted below each bar: Placebo (N=84) and Levetiracetam (N=79). An asterisk highlights the levetiracetam bar.*
100 mL/4 Oz (Levetiracetam Oral Solution 8)
Label for Levetiracetam Oral Solution, USP 100 mg/mL by Amneal Pharmaceuticals LLC. The label includes dosing storage instructions, pharmacist warnings, and NDC 65162-685-86. The net contents are 4 fl oz (118 mL), with a barcode and Amneal logo present.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
